Mannin Research
2012
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
Accelerator/Inc
LATEST DEAL TYPE
1
INVESTORS
Description
Developer of vascular therapeutics designed to glaucoma and cystic kidney diseases. The company's vascular therapeutics uses Tie2 mechanism of action, enabling medical professional to treat glaucoma and cystic kidney diseases and patients to get relief from these diseases.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Q BioMed
Primary Office
- 629 Eastern Avenue
- Suite C300
- Toronto, Ontario M4M 1E4
- Canada
+1 (416) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Mannin Research’s full profile, request a free trial.
Mannin Research Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 02-Feb-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Merger/Acquisition | 13-Jan-2016 | Completed | Startup |
Mannin Research Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Matter | Accelerator/Incubator | 000 0000 | 000000 0 |
Mannin Research Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| George Nikopoulos Ph.D | Chief Executive Officer and President | ||
| Susan Quaggin | Chief Scientific Officer and Director | ||
| Christopher Smith | Chairman |
Mannin Research Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Christopher Smith | Mannin Research | Chairman | 000 0000 | |
| Geoffrey Smith | Mannin Research | Board Member | 000 0000 |